ProPhase Labs, Inc.
ProPhase Labs, Inc. (PRPH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
prph · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ProPhase Labs, Inc. (PRPH) measures how much investors pay for each dollar of the company's trailing earnings. PRPH's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$1.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%6.4x
MedianQ3 · 75%125.9x
Max
At N/A, PRPH's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ProPhase Labs, Inc.You PRPH | $0M | N/A | — | -$1.74 |
 Adaptimmune Therapeutics plc ADAP | $75M | N/A | — | -$0.28 |
 Aethlon Medical, Inc. AEMD | $2M | N/A | — | -$85.77 |
 Allurion Technologies Inc. ALUR | $6M | N/A | — | -$0.38 |
 Aytu BioPharma, Inc. AYTU | $19M | N/A | — | -$2.16 |
 Biofrontera Inc. BFRI | $12M | N/A | — | -$1.04 |
 Co-Diagnostics, Inc. CODX | $6M | N/A | — | -$35.25 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.74 | — | |
2024-12-31 FY2024 | — | $-27.97 | — | |
2023-12-31 FY2023 | — | $-9.75 | — | |
2022-12-31 FY2022 | 4.14x | $11.65 | -52.4% | |
2021-12-31 FY2021 | 8.68x | $4.13 | — | |
2020-12-31 FY2020 | — | $-1.83 | — | |
2019-12-31 FY2019 | — | $-2.72 | — | |
2018-12-31 FY2018 | — | $-1.53 | — | |
2017-12-31 FY2017 | 1.61x | $26.88 | — | |
2016-12-31 FY2016 | — | $-1.72 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ProPhase Labs, Inc. (PRPH) measures how much investors pay for each dollar of the company's trailing earnings. PRPH's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$1.74.
Frequently asked questions
PRPH pe ratio · 6 questionsPRPH's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.10 and TTM EPS of -$1.74. Data sourced from Financial Modeling Prep via PRPH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ProPhase Labs, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09